Bevacizumab: Optimal dose, schedule, and duration of therapy

David R Gandara, Randeep Sangha, Angela M. Davies

Research output: Contribution to journalArticle

2 Citations (Scopus)
Original languageEnglish (US)
Pages (from-to)522-523
Number of pages2
JournalClinical Lung Cancer
Volume8
Issue number9
StatePublished - Nov 2007

Fingerprint

Drug Administration Schedule
Antineoplastic Combined Chemotherapy Protocols
Deoxycytidine
Angiogenesis Inhibitors
Neoplasm Staging
Carboplatin
Paclitaxel
Non-Small Cell Lung Carcinoma
Vascular Endothelial Growth Factor A
Cisplatin
Lung Neoplasms
Appointments and Schedules
Monoclonal Antibodies
Therapeutics
Bevacizumab

ASJC Scopus subject areas

  • Cancer Research
  • Pulmonary and Respiratory Medicine

Cite this

Bevacizumab : Optimal dose, schedule, and duration of therapy. / Gandara, David R; Sangha, Randeep; Davies, Angela M.

In: Clinical Lung Cancer, Vol. 8, No. 9, 11.2007, p. 522-523.

Research output: Contribution to journalArticle

Gandara, DR, Sangha, R & Davies, AM 2007, 'Bevacizumab: Optimal dose, schedule, and duration of therapy', Clinical Lung Cancer, vol. 8, no. 9, pp. 522-523.
Gandara, David R ; Sangha, Randeep ; Davies, Angela M. / Bevacizumab : Optimal dose, schedule, and duration of therapy. In: Clinical Lung Cancer. 2007 ; Vol. 8, No. 9. pp. 522-523.
@article{3a85745ca85441d2ac48d203a466fb9a,
title = "Bevacizumab: Optimal dose, schedule, and duration of therapy",
author = "Gandara, {David R} and Randeep Sangha and Davies, {Angela M.}",
year = "2007",
month = "11",
language = "English (US)",
volume = "8",
pages = "522--523",
journal = "Clinical Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier",
number = "9",

}

TY - JOUR

T1 - Bevacizumab

T2 - Optimal dose, schedule, and duration of therapy

AU - Gandara, David R

AU - Sangha, Randeep

AU - Davies, Angela M.

PY - 2007/11

Y1 - 2007/11

UR - http://www.scopus.com/inward/record.url?scp=37349124748&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37349124748&partnerID=8YFLogxK

M3 - Article

C2 - 18186957

AN - SCOPUS:37349124748

VL - 8

SP - 522

EP - 523

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

SN - 1525-7304

IS - 9

ER -